The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Outcomes with multikinase inhibitors after progression on first-line atezolizumab-bevacizumab in HCC
Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Republic of Korea, discusses the results of a multinational, multicenter, retrospective study assessing clinical outcomes of patients with advanced hepatocellular carcinoma (HCC) who received subsequent systemic therapy after progression on atezolizumab-bevacizumab in Korea, Hong Kong, and Singapore. Second-line treatment with multikinase inhibitors demonstrated comparable efficacy and manageable toxicities in patients with advanced HCC after disease progression. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
